NANOARC | CONSULTING reposted this
The premature release of a drug has implications on the treatment of systemic and intracellular infections. #Nanoparticles are retained for much longer periods than conventional therapeutics in the body and this retainment enables a slow and sustained release of therapeutic agents. This is important because under conditions of controlled and sustained release, the goal is to ensure, that the drug concentration is maintained within the therapeutic window, thereby also decreasing the possibility of #drugresistance. These characteristics of nanoparticles are relevant in antiviral therapy in which the high dose of a drug is needed and the drugs are often very expensive. Usage of nanoparticulate carriers can reduce the frequency of the #drug intake as well as treatment timeframes, thus enhancing the effectiveness of an approved #therapeutic drug and overcome its limitations, such as low bioavailability. SOME DESIGN FACTORS Nanoparticle uptake is an important consideration in the design of nano-therapeutics, because this will have a direct influence on the therapeutic load, and hence the appropriate dose, entering the cells. Subsequent #biodegradation of the nanoparticles is critical determining the sustained release of a drug and subsequent biodistribution profiles. If biodegradation does not occur, the nanoparticle must eventually exit the cell and be excreted from the body. If nanoparticles are too large to undergo renal clearance, they may accumulate in the body. Smaller particles however (< 5 nm), can be excreted in urine. It is expected that the usage of quantum materials (typically < 20 nm in diameter) with high surface area in antiviral therapeutic processes will have positive effects in the treatment of #infectiousdiseases. These nanoparticles could potentially improve the efficacy of e.g #cancer , #diabetes, #antiviral and related drugs, to reduce the adverse side effects of such drugs on the body. OUR OFFER Therapeutic targeting of pathogens using surface-modified appropriately scaled nanoparticles is a strategy, that permits drug delivery at the organ or even cellular level. We specialise in the development and manufacture of high surface area, sub 20 nm particles. We offer them as ligand-free #nanopowder, for controlled dosage within therapeutic drugs. In the absence of ligands, there is ample surface area on the nanoparticles for the addition of the necessary amount of therapeutic molecules. The flexibility in surface functionalisation implies the nanoparticle charge can be modified to facilitate cellular uptake, when dispersed in the appropriate biocompatible medium of choice. Coupled with the advantages of slow and sustained drug release, in order to make the drug(s) more #bioavailable, there is a potential in lowering the likelihood of adverse side effects. from high drug doses. More at https://lnkd.in/esE6VFe7 #nanotechnology #drugdelivery #drugdevelopment #pharmaceuticals #biotech #biomedicine